ACP
FOLD

Acuta Capital Partners’s Amicus Therapeutics FOLD Stock Holding History

Acuta Capital Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-151,000
Closed -$2.28M – 81
2017
Q3 		$2.28M Buy
+151,000
New +$2M 0.41% 37

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Acuta Capital Partners's FOLD Position: Q4 2022 in Review

Acuta Capital Partners sold out of Amicus Therapeutics (FOLD) in Q4 2022, closing a stake of 290,000 shares — an estimated $3.03M sold.

Acuta Capital Partners first reported a position in FOLD in Q4 2014 and held it in 14 quarters. The position peaked at $25.1M in Q2 2015. 230 funds tracked by Wall St. Rank hold FOLD as of Q4 2022.

  • Acuta Capital Partners reported no remaining Amicus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 290,000 Amicus Therapeutics shares in Q4 2022, an estimated $3.03M.
  • Acuta Capital Partners first reported a position in Amicus Therapeutics in Q4 2014 and held it in 14 quarters.
  • Acuta Capital Partners's Amicus Therapeutics position peaked at $25.1M in Q2 2015.
  • 230 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2022.

Based on Acuta Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.